In the treatment with anti-PD-1 agents, depigmentation is induced by the activation of CD8+ cytotoxic T cells against melanoma-associated antigens (MART-1/MelanA, gp100, and tyrosinase-related proteins 1 and 2) shared by normal melanocytes and melanomas (18, 68). The gene discussed is RPL17; the disease is melanoma.